|
1
|
Rizvi S and Gores GJ: Pathogenesis,
diagnosis, and management of cholangiocarcinoma. Gastroenterology.
145:1215–1229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kelley RK, Bridgewater J, Gores GJ and Zhu
AX: Systemic therapies for intrahepatic cholangiocarcinoma. J
Hepatol. 72:353–363. 2020. View Article : Google Scholar
|
|
3
|
Lunsford KE, Javle M, Heyne K, Shroff RT,
Abdel-Wahab R, Gupta N, Mobley CM, Saharia A, Victor DW, Nguyen DT,
et al: Liver transplantation for locally advanced intrahepatic
cholangiocarcinoma treated with neoadjuvant therapy: A prospective
case-series. Lancet Gastroenterol Hepatol. 3:337–348. 2018.
View Article : Google Scholar
|
|
4
|
El-Diwany R, Pawlik TM and Ejaz A:
Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 28:587–599.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Martin SG and St Johnston D: A role for
Drosophila LKB1 in anterior-posterior axis formation and epithelial
polarity. Nature. 421:379–384. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shaw RJ, Kosmatka M, Bardeesy N, Hurley
RL, Witters LA, DePinho RA and Cantley LC: The tumor suppressor
LKB1 kinase directly activates AMP-activated kinase and regulates
apoptosis in response to energy stress. Proc Natl Acad Sci USA.
101:3329–3335. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li N, Huang D, Lu N and Luo L: Role of the
LKB1/AMPK pathway in tumor invasion and metastasis of cancer cells
(review). Oncol Rep. 34:2821–2826. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jin LY, Zhao K, Xu LJ, Zhao RX, Werle KD,
Wang Y, Liu XL, Chen Q, Wu ZJ, Zhang K, et al: LKB1 inactivation
leads to centromere defects and genome instability via
p53-dependent upregulation of survivin. Aging (Albany NY).
12:14341–14354. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koyama S, Akbay EA, Li YY, Aref AR,
Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM,
Denning WL, et al: STK11/LKB1 deficiency promotes neutrophil
recruitment and proinflammatory cytokine production to suppress
T-cell activity in the lung tumor microenvironment. Cancer Res.
76:999–1008. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Skoulidis F, Goldberg ME, Greenawalt DM,
Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco
SE, Gay L, et al: STK11/LKB1 mutations and PD-1 inhibitor
resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov.
8:822–835. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kitajima S, Ivanova E, Guo S, Yoshida R,
Campisi M, Sundararaman SK, Tange S, Mitsuishi Y, Thai TC, Masuda
S, et al: Suppression of STING associated with LKB1 loss in
KRAS-driven lung cancer. Cancer Discov. 9:34–45. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shukuya T, Yamada T, Koenig MJ, Xu J,
Okimoto T, Li F, Amann JM and Carbone DP: The effect of LKB1
activity on the sensitivity to PI3K/mTOR inhibition in non-small
cell lung cancer. J Thorac Oncol. 14:1061–1076. 2019. View Article : Google Scholar
|
|
13
|
Moro M, Caiola E, Ganzinelli M, Zulato E,
Rulli E, Marabese M, Centonze G, Busico A, Pastorino U, de Braud
FG, et al: Metformin enhances cisplatin-induced apoptosis and
prevents resistance to cisplatin in co-mutated KRAS/LKB1 NSCLC. J
Thorac Oncol. 13:1692–1704. 2018. View Article : Google Scholar
|
|
14
|
Gao Y, Yan Y, Tripathi S, Pentinmikko N,
Amaral A, Päivinen P, Domènech-Moreno E, Andersson S, Wong IPL,
Clevers H, et al: LKB1 represses ATOH1 via PDK4 and energy
metabolism and regulates intestinal stem cell fate.
Gastroenterology. 158:1389–1401.e10. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shan T, Xu Z, Liu J, Wu W and Wang Y: Lkb1
regulation of skeletal muscle development, metabolism and muscle
progenitor cell homeostasis. J Cell Physiol. 232:2653–2656. 2017.
View Article : Google Scholar
|
|
16
|
Zhang Y, Meng Q, Sun Q, Xu ZX, Zhou H and
Wang Y: LKB1 deficiency-induced metabolic reprogramming in
tumorigenesis and non-neoplastic diseases. Mol Metab.
44:1011312021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maillet V, Boussetta N, Leclerc J, Fauveau
V, Foretz M, Viollet B, Couty JP, Celton-Morizur S, Perret C and
Desdouets C: LKB1 as a gatekeeper of hepatocyte proliferation and
genomic integrity during liver regeneration. Cell Rep.
22:1994–2005. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang D, Zhang W, Zhang H, Zhang F, Chen L,
Ma L, Larcher LM, Chen S, Liu N, Zhao Q, et al: Progress,
opportunity, and perspective on exosome isolation-efforts for
efficient exosome-based theranostics. Theranostics. 10:3684–3707.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van Niel G, D'Angelo G and Raposo G:
Shedding light on the cell biology of extracellular vesicles. Nat
Rev Mol Cell Biol. 19:213–228. 2018. View Article : Google Scholar
|
|
20
|
Kalluri R and LeBleu VS: The biology,
function, and biomedical applications of exosomes. Science.
367:eaau69772020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fabris L, Sato K, Alpini G and
Strazzabosco M: The tumor microenvironment in cholangiocarcinoma
progression. Hepatology. 73 (Suppl 1):S75–S85. 2021. View Article : Google Scholar
|
|
22
|
Sinha D, Roy S, Saha P, Chatterjee N and
Bishayee A: Trends in research on exosomes in cancer progression
and anticancer therapy. Cancers (Basel). 13:3262021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang ZJ, Zhang LL, Bi QC, Gan LJ, Wei MJ,
Hong T, Tan RJ, Lan XM, Liu LH, Han XJ and Jiang LP: Exosomal
connexin 43 regulates the resistance of glioma cells to
temozolomide. Oncol Rep. 45:442021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang S, Hu Y, Lv X, Li B, Gu D, Li Y, Sun
Y and Su Y: Circ-0000284 arouses malignant phenotype of
cholangiocarcinoma cells and regulates the biological functions of
peripheral cells through cellular communication. Clin Sci (Lond).
133:1935–1953. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang X, Miao R, Liu T, Xiang X, Gu J, Jia
Y, Li Z, Fu Y, He Y, Zhang Y, et al: IDH1 as a frequently mutated
gene has potential effect on exosomes releasement by epigenetically
regulating P2RX7 in intrahepatic cholangiocarcinoma. Biomed
Pharmacother. 113:1087742019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rizvi S, Khan SA, Hallemeier CL, Kelley RK
and Gores GJ: Cholangiocarcinoma-evolving concepts and therapeutic
strategies. Nat Rev Clin Oncol. 15:95–111. 2018. View Article : Google Scholar
|
|
27
|
Liu Z, Li S, Zeng J, Zhou X, Li H, Liu X,
Li F, Jiang B, Zhao M and Ma T: LKB1 inhibits intrahepatic
cholangiocarcinoma by repressing the transcriptional activity of
the immune checkpoint PD-L1. Life Sci. 257:1180682020. View Article : Google Scholar
|
|
28
|
Théry C, Amigorena S, Raposo G and Clayton
A: Isolation and characterization of exosomes from cell culture
supernatants and biological fluids. Curr Protoc Cell Biol Chapter
3: Unit 3.22. 2006.
|
|
29
|
Shang S, Wang J, Chen S, Tian R, Zeng H,
Wang L, Xia M, Zhu H and Zuo C: Exosomal miRNA-1231 derived from
bone marrow mesenchymal stem cells inhibits the activity of
pancreatic cancer. Cancer Med. 8:7728–7740. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Santarpia M, Aguilar A, Chaib I, Cardona
AF, Fancelli S, Laguia F, Bracht JWP, Cao P, Molina-Vila MA,
Karachaliou N and Rosell R: Non-small-cell lung cancer signaling
pathways, metabolism, and PD-1/PD-L1 antibodies. Cancers (Basel).
12:14752020. View Article : Google Scholar
|
|
31
|
Xu C, Fillmore CM, Koyama S, Wu H, Zhao Y,
Chen Z, Herter-Sprie GS, Akbay EA, Tchaicha JH, Altabef A, et al:
Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with
elevated PD-L1 expression. Cancer Cell. 25:590–604. 2014.
View Article : Google Scholar
|
|
32
|
Saha SK, Gordan JD, Kleinstiver BP, Vu P,
Najem MS, Yeo JC, Shi L, Kato Y, Levin RS, Webber JT, et al:
Isocitrate dehydrogenase mutations confer dasatinib
hypersensitivity and SRC dependence in intrahepatic
cholangiocarcinoma. Cancer Discov. 6:727–739. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gao Q, Zhao YJ, Wang XY, Guo WJ, Gao S,
Wei L, Shi JY, Shi GM, Wang ZC, Zhang YN, et al: Activating
mutations in PTPN3 promote cholangiocarcinoma cell proliferation
and migration and are associated with tumor recurrence in patients.
Gastroenterology. 146:1397–1407. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fan S, Ge Y, Liu J, Liu H, Yan R, Gao T,
Fan X, Xiao Z and An G: Combination of anlotinib and gemcitabine
promotes the G0/G1 cell cycle arrest and apoptosis of intrahepatic
cholangiocarcinoma in vitro. J Clin Lab Anal. 35:e239862021.
View Article : Google Scholar
|
|
35
|
Tang L, Wang Y, Wang H, Xu B, Ji H, Xu G,
Ge X, Li Q and Miao L: Long noncoding-RNA component of
mitochondrial RNA processing endoribonuclease is involved in the
progression of cholangiocarcinoma by regulating microRNA-217.
Cancer Sci. 110:2166–2179. 2019. View Article : Google Scholar
|
|
36
|
Yang X, Wang S, Mu Y and Zheng Y:
Schisandrin B inhibits cell proliferation and induces apoptosis in
human cholangiocarcinoma cells. Oncol Rep. 36:1799–1806. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Enjoji M, Sakai H, Nawata H, Kajiyama K
and Tsuneyoshi M: Sarcomatous and adenocarcinoma cell lines from
the same nodule of cholangiocarcinoma. In Vitro Cell Dev Biol Anim.
33:681–683. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen G, Huang AC, Zhang W, Zhang G, Wu M,
Xu W, Yu Z, Yang J, Wang B, Sun H, et al: Exosomal PD-L1
contributes to immunosuppression and is associated with anti-PD-1
response. Nature. 560:382–386. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Deng R, Zuo C, Li Y, Xue B, Xun Z, Guo Y,
Wang X, Xu Y, Tian R, Chen S, et al: The innate immune effector
ISG12a promotes cancer immunity by suppressing the canonical
Wnt/β-catenin signaling pathway. Cell Mol Immunol. 17:1163–1179.
2020. View Article : Google Scholar
|
|
40
|
Alzahrani AS: PI3K/Akt/mTOR inhibitors in
cancer: At the bench and bedside. Semin Cancer Biol. 59:125–132.
2019. View Article : Google Scholar
|
|
41
|
He PX, Ma ZL, Han H, Zhang XY, Niu SH, Du
LN, Zheng YC and Liu HM: Expression of programmed death ligand 1
(PD-L1) is associated with metastasis and differentiation in
gastric cancer. Life Sci. 242:1172472020. View Article : Google Scholar
|
|
42
|
Deneka AY, Kopp MC, Nikonova AS, Gaponova
AV, Kiseleva AA, Hensley HH, Flieder DB, Serebriiskii IG and
Golemis EA: Nedd9 restrains autophagy to limit growth of early
stage non-small cell lung cancer. Cancer Res. 81:3717–3726. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chou WC, Rampanelli E, Li X and Ting JP:
Impact of intracellular innate immune receptors on
immunometabolism. Cell Mol Immunol. 19:337–351. 2022. View Article : Google Scholar
|
|
44
|
Gao X, Mi Y, Guo N, Luan J, Xu H, Hu Z,
Wang N, Zhang D, Gou X and Xu L: The mechanism of propofol in
cancer development: An updated review. Asia Pac J Clin Oncol.
16:e3–e11. 2020. View Article : Google Scholar
|
|
45
|
Kanada M, Bachmann MH and Contag CH:
Signaling by extracellular vesicles advances cancer hallmarks.
Trends Cancer. 2:84–94. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Nakaoka A, Nakahana M, Inubushi S, Akasaka
H, Salah M, Fujita Y, Kubota H, Hassan M, Nishikawa R, Mukumoto N,
et al: Exosome-mediated radiosensitizing effect on neighboring
cancer cells via increase in intracellular levels of reactive
oxygen species. Oncol Rep. 45:132021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rodrigues G, Hoshino A, Kenific CM, Matei
IR, Steiner L, Freitas D, Kim HS, Oxley PR, Scandariato I,
Casanova-Salas I, et al: Tumour exosomal CEMIP protein promotes
cancer cell colonization in brain metastasis. Nat Cell Biol.
21:1403–1412. 2019. View Article : Google Scholar
|
|
48
|
Peinado H, Alečković M, Lavotshkin S,
Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M,
Williams C, Garcia-Santos G, Ghajar C, et al: Melanoma exosomes
educate bone marrow progenitor cells toward a pro-metastatic
phenotype through MET. Nat Med. 18:883–891. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hoshino A, Costa-Silva B, Shen TL,
Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di
Giannatale A, Ceder S, et al: Tumour exosome integrins determine
organotropic metastasis. Nature. 527:329–335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Skog J, Wurdinger T, van Rijn S, Meijer
DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky
AM and Breakefield XO: Glioblastoma microvesicles transport RNA and
proteins that promote tumour growth and provide diagnostic
biomarkers. Nat Cell Biol. 10:1470–1476. 2008. View Article : Google Scholar
|
|
51
|
Yu W, Hurley J, Roberts D, Chakrabortty
SK, Enderle D, Noerholm M, Breakefield XO and Skog JK:
Exosome-based liquid biopsies in cancer: Opportunities and
challenges. Ann Oncol. 32:466–477. 2021. View Article : Google Scholar
|
|
52
|
Hannafon BN, Trigoso YD, Calloway CL, Zhao
YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC and Ding WQ:
Plasma exosome microRNAs are indicative of breast cancer. Breast
Cancer Res. 18:902016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Choi D, Montermini L, Kim DK, Meehan B,
Roth FP and Rak J: The impact of oncogenic EGFRvIII on the proteome
of extracellular vesicles released from glioblastoma cells. Mol
Cell Proteomics. 17:1948–1964. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Matsumoto Y, Kano M, Akutsu Y, Hanari N,
Hoshino I, Murakami K, Usui A, Suito H, Takahashi M, Otsuka R, et
al: Quantification of plasma exosome is a potential prognostic
marker for esophageal squamous cell carcinoma. Oncol Rep.
36:2535–2543. 2016. View Article : Google Scholar : PubMed/NCBI
|
